Loading…
← CockpitCompetitor Analysis › ANGO AngioDynamics, Inc.Open in the cockpit ↗

AngioDynamics, Inc.ANGOCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum weak 31
Mkt cap
$476M
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$6.11M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-17.5 pp
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
50 days
7 Jan 2027
Close · USD$11.32
1D-1.5%
1W-8.9%
1M-4.2%
3M-28.4%
6M-4.2%
YTD-11.8%
1Y-5.0%
ATR %4.6%
Beta1.05
52w lowhigh30.5% off high

What AngioDynamics does

Employees: 632

AngioDynamics at a glance

Size AngioDynamics (ANGO) is a United States Health Care company (Medical Specialties) with a market value of $476M, the 2705th largest of 3,085 United States companies the cockpit tracks. Shares closed at $11.32 on 18 Nov 2026.

Performance Over six months the shares fell 4.2%, against -20.2% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 8.2% over the last twelve months (peer median +1.9%); the operating margin is -6.0% (peer median 2.7%).

Valuation It trades at 1.4× enterprise value to sales against a peer median of 2.7× (3rd cheapest of 19).

Capital Return on invested capital runs 17.5 points below its cost of capital (6.5% WACC).

Short interest Short interest is 4.8% of the free float (30 Oct 2026).

Next results Next results expected around 7 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026ANGO 95Peer median 82
Six months, rebased to 100: AngioDynamics against the median of its 20 peers (local-currency closes).

AngioDynamics financials

Reported figures in USD; fiscal year ends 2026-05-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$325M$320M$292M$304M$339M
Revenue growth—+9%-4%-10%—
Gross profit$170M$164M$147M$142M$155M
EBITDA$2.88M-$1.15M-$244,000-$6.10M$14.5M
Net income-$32.9M-$36.7M-$34.0M-$184M-$52.4M
Free cash flow-$3.87M-$2.86M-$21.0M-$35.7M-$9.13M
Capital expenditure$7.55M$5.95M$10.2M$10.8M$9.75M
Total debt$10.7M$11.0M$3.95M$5.91M$55.1M

Quarterly statements and history in the cockpit →

AngioDynamics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%CEVI3002466033093010336886060029324549MDXG603520300289468530MEDX688580002016603987AVR7979CU6ANGO6-month return →1-month return →
Up and to the right = strong over both horizons. AngioDynamics is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%+50%0×200×400×CEVI300246301033MDXG300289468530MEDX688298002016688075AVRANGORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. AngioDynamics is the large dot.

AngioDynamics competitors and peer comparison

How AngioDynamics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

AngioDynamics against its 20 peers (data as of 18 Nov 2026)
MeasureANGOPeer medianRank in peer set
1-month return-4.2%-6.1%10th highest of 21
6-month return-4.2%-20.2%5th highest of 21
Distance from 52-week high-30.5%-43.4%5th highest of 21
Revenue growth (TTM)+8.2%+1.9%7th highest of 20
Operating margin-6.0%2.7%8th lowest of 20
EV / Sales1.4×2.7×3rd cheapest of 19
ROIC minus cost of capital-17.5 pp-1.6 pp2nd lowest of 18
Net debt / EBITDA-8.1×-1.0×least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
AngioDynamics ANGOUnited States$476M-4%+8%-6%1.4×n/an/a
CellaVision CEVI.STSweden$477M+64%+2%23%6.1×7.1%+10.0%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%3.1×55.3%-4.7%
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%15%2.0×-5.9%+7.7%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%7.0×4.3%+24.4%
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%1.3×-6.5%-4.3%
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Eiken Chemical 4549.TJapan$466M-20%+4%6%1.6×n/an/a
MiMedx MDXGUnited States$464M-16%-23%-8%1.1×10.9%+11.0%
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%2.2×n/an/a
Beijing Leadman Biochemistry 300289.SZChina$460M-9%+46%1%8.2×36.0%-6.9%
PROTEINA 468530.KSSouth Korea$460M+5%-59%-1,178%410.3×n/an/a
medmix MEDX.SWSwitzerland$494M+11%-7%6%1.4×4.5%+5.0%
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%5.3×20.1%+4.2%
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%1.6×n/an/a
Guangdong Shirongzhaoye 002016.SZChina$453M-26%-31%3%3.8×21.5%-11.7%
Shanghai Kindly Enterprises Development 603987.SSChina$452M-12%0%10%1.5×-1.0%-2.8%
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%5.4×30.8%-18.6%
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%125.0×n/an/a
Shofu 7979.TJapan$510M+32%+9%14%1.6×n/an/a
Clarity Pharmaceuticals CU6.AXAustralia$444M-33%n/an/an/an/an/a

Questions

Which companies are AngioDynamics's closest peers?
The cockpit's peer set: CellaVision (CEVI.ST), Guangdong Biolight Meditech (300246.SZ), WELL LEAD MEDICAL (603309.SS), Medprin Regenerative Medical Technologies (301033.SZ), Hangzhou Alltest Biotech (688606.SS), Wuhan Easy Diagnosis Biomedicine (002932.SZ), Eiken Chemical (4549.T), MiMedx (MDXG).
Is AngioDynamics expensive compared with its peers?
On ev / sales it trades at 1.4× against a peer median of 2.7×, 3rd cheapest of 19 in its peer set.
How has AngioDynamics stock performed?
Over six months to 18 Nov 2026 the shares returned -4.2% against -20.2% for the median peer; over one year -5.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.